|
| |
Challenges and Opportunities in the Global Protein
Therapeutics Market
http://www.arrowheadpublishers.com/ProteinTherapeutics.html
The global protein therapeutics market
was valued at US$57 billion in 2005 according to Arrowhead Publishers’ new
report The Global Protein Therapeutics Market – Market Dynamics and Pipeline
Analysis. Biotechnology has made notable inroads in the field of protein
therapeutics, resulting in some of the key products presently available in the
category. Recombinant proteins are potentially advantageous in terms of higher
efficacy and fewer side effects than other pharmaceutical products, as they can
be more specifically targeted to the cause of the disease, rather than the
treatment of its symptoms.
Key Drivers and Restraints
In 2005, the antibodies market was valued at an
estimated US$13.6 billion, accounting for over 24 percent of the total biotech
protein therapeutics market. Cancer is the fastest-growing therapeutic areas for
MAbs. The segment is boosted by the fact that 50 percent of all drug targets are
cell-surface proteins, with most cancer targets also being proteins.
After tremendous growth during the first few
years of the new millenium, the erythropoietin market is beginning to cool down.
Two out of the four key erythropoietin products have experienced a decline in
revenue in 2005. The older generation epoetin alfa products Procrit/Exprex and
Epogen are losing market ground to Aranesp, the relatively new darbepoetin alfa
product from Amgen.
After a disappointing 2004, revenues from sales
of alpha interferons increased by 18 percent in 2005. This was due to increased
sales of both Pegasys as well as PEG-Intron. The sudden increase in PEG-Intron
revenues was due to the recent approval of Rebetron (ribavirin + Intron) in
Japan.
The insulin market has grown at a steady
double-digit pace in recent years, boosted by the wider use of insulin in late
stage Type 2 diabetes. Additionally, the use of insulin analogs has increased
(due to their suitability for variable and flexible dosing), as has the use of
more convenient delivery technologies, such as pre-filled pens. Such devices are
more expensive than traditional syringes, which has pushed up the value of the
market.
Medical and technological advances will continue
to stimulate growth in the market for colony stimulating factors. Drivers of
growth will outweigh its restraints, although the increased competition will
continue to push smaller players out of the market. Emerging CSF therapies will
enter the equation only in the long term, by which time Amgen’s dominance will
be entrenched.
Key restraints in the protein therapeutics
market include: cost of production, treatment regimen compliance (given the
reliance on injectable drug delivery for the administration of protein
molecules), immunogenicity and the difficulties in securing reimbursement for
such costly and long-term treatments of chronic diseases.
Outlook
The discovery of new protein therapeutics will
be facilitated by the development of genetics and related disciplines, which
will result in an increasing number of protein-based drugs on the market.
Competition will continue to intensify in the coming years, especially in key
therapeutic areas, such as cancer and autoimmune diseases. The trend will be
particularly prominent in the areas in which protein therapy is the only viable
treatment. Research efforts in this field are numerous, given the diversity of
sources for therapeutic proteins (including recombinant DNA), as well as their
ability to target interactions inaccessible to small molecules.
Arrowhead Publishers’ new report: The Global
Protein Therapeutics Market – Market Dynamics and Pipeline Analysis is now
available. For sample pages or ordering information, please contact us at
1-612-929-5203, email us at
sales@arrowheadpublishers.net or visit our website:
www.arrowheadpublishers.com
| |
|
